Expert Interview
A Third Look: Discussing avutometinib from Verastem and its phase 1/2 trials RAMP 201 (Part A and B) & 203 trials (combo with KRAS for LGSOC or low grade serous ovarian cancer)
Ticker(s): VSTMInstitution: University of Colorado
- Program director for gynecologic oncology and vice chair of education for ob/gyn department
- Treats a broad range of patient needs, including precancers and cancers of the cervix, ovary, uterus, vagina and vulva
- Member of the Society of Gynecologic Oncologists and the American Association of Hospice and Palliative Medicine.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
